source
- Biotech sector eyes key clinical trial readouts in H2 2026 across cancer, Alzheimer’s and autoimmune diseasesThe first half of 2026 saw a surge in biotech activity, with record‑high deal flow, several large IPOs and a regulatory environment that appears to be stabilising after a period of uncertainty. An…
- NEJM retracts pivotal data for Amgen's Tavneos, adding new hurdle for the autoimmune drugThe New England Journal of Medicine has withdrawn the pivotal data that supported Amgen’s autoimmune therapy Tavneos. The retraction was requested by two academic authors who raised concerns about…